Titre : Capacité mentale

Capacité mentale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin Receptor Antagonists
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Capacité mentale : Questions médicales les plus fréquentes", "headline": "Capacité mentale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Capacité mentale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Capacité mentale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Jurisprudence", "url": "https://questionsmedicales.fr/mesh/D007603", "about": { "@type": "MedicalCondition", "name": "Jurisprudence", "code": { "@type": "MedicalCode", "code": "D007603", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.706.535" } } }, "about": { "@type": "MedicalCondition", "name": "Capacité mentale", "alternateName": "Mental Competency", "code": { "@type": "MedicalCode", "code": "D016743", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jane Meschan Foy", "url": "https://questionsmedicales.fr/author/Jane%20Meschan%20Foy", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, School of Medicine, Wake Forest University, Winston-Salem, North Carolina; foy.jane@gmail.com." } }, { "@type": "Person", "name": "Cori M Green", "url": "https://questionsmedicales.fr/author/Cori%20M%20Green", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, New York; and." } }, { "@type": "Person", "name": "Marian F Earls", "url": "https://questionsmedicales.fr/author/Marian%20F%20Earls", "affiliation": { "@type": "Organization", "name": "Community Care of North Carolina, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Cori Green", "url": "https://questionsmedicales.fr/author/Cori%20Green", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Weill Cornell Medicine, New York, New York; cmg9004@med.cornell.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.", "datePublished": "2023-05-18", "url": "https://questionsmedicales.fr/article/37231800", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000530988" } }, { "@type": "ScholarlyArticle", "name": "Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36682353", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000528783" } }, { "@type": "ScholarlyArticle", "name": "Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37421275", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1161/JAHA.122.028865" } }, { "@type": "ScholarlyArticle", "name": "Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort.", "datePublished": "2023-03-27", "url": "https://questionsmedicales.fr/article/37016775", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.32725/jab.2023.002" } }, { "@type": "ScholarlyArticle", "name": "Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction.", "datePublished": "2023-03-09", "url": "https://questionsmedicales.fr/article/36893150", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0281460" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Contrôle social formel", "item": "https://questionsmedicales.fr/mesh/D012926" }, { "@type": "ListItem", "position": 4, "name": "Jurisprudence", "item": "https://questionsmedicales.fr/mesh/D007603" }, { "@type": "ListItem", "position": 5, "name": "Capacité mentale", "item": "https://questionsmedicales.fr/mesh/D016743" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Capacité mentale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Capacité mentale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Capacité mentale", "description": "Comment évaluer la capacité mentale d'un patient ?\nQuels signes indiquent une altération de la capacité mentale ?\nQuels professionnels évaluent la capacité mentale ?\nQuelles échelles sont utilisées pour le diagnostic ?\nQuand consulter un spécialiste pour un diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Capacité mentale", "description": "Quels sont les symptômes d'une capacité mentale altérée ?\nLa dépression affecte-t-elle la capacité mentale ?\nComment le stress impacte-t-il la capacité mentale ?\nLes troubles du sommeil influencent-ils la capacité mentale ?\nQuels changements de comportement signalent une altération ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Capacité mentale", "description": "Comment prévenir l'altération de la capacité mentale ?\nL'alimentation influence-t-elle la capacité mentale ?\nLe contrôle du stress est-il important ?\nLes activités mentales préventives sont-elles efficaces ?\nLe suivi médical régulier est-il nécessaire ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Capacité mentale", "description": "Quels traitements existent pour améliorer la capacité mentale ?\nLa rééducation cognitive est-elle efficace ?\nQuels médicaments peuvent aider à la capacité mentale ?\nLa thérapie de groupe est-elle bénéfique ?\nLes exercices physiques aident-ils la capacité mentale ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Capacité mentale", "description": "Quelles complications peuvent résulter d'une capacité mentale altérée ?\nL'isolement social est-il une complication fréquente ?\nLes accidents sont-ils plus fréquents chez ces patients ?\nComment la capacité mentale altérée affecte-t-elle les relations ?\nLes troubles mentaux peuvent-ils aggraver d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Capacité mentale", "description": "Quels sont les facteurs de risque pour une altération de la capacité mentale ?\nLe tabagisme influence-t-il la capacité mentale ?\nLe manque d'activité physique est-il un facteur de risque ?\nLes traumatismes crâniens augmentent-ils le risque ?\nLes troubles de l'humeur sont-ils des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D016743?mesh_terms=Angiotensin+Receptor+Antagonists&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la capacité mentale d'un patient ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par des tests psychométriques et des entretiens cliniques." } }, { "@type": "Question", "name": "Quels signes indiquent une altération de la capacité mentale ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Confusion, désorientation, incapacité à prendre des décisions éclairées." } }, { "@type": "Question", "name": "Quels professionnels évaluent la capacité mentale ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Psychologues, psychiatres et médecins généralistes sont impliqués dans l'évaluation." } }, { "@type": "Question", "name": "Quelles échelles sont utilisées pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'échelle de Mini-Mental State Examination (MMSE) est couramment utilisée." } }, { "@type": "Question", "name": "Quand consulter un spécialiste pour un diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Si des changements de comportement ou de cognition sont observés, consultez un spécialiste." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une capacité mentale altérée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Difficultés de concentration, mémoire défaillante, jugement altéré." } }, { "@type": "Question", "name": "La dépression affecte-t-elle la capacité mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la dépression peut altérer la concentration et le jugement, affectant la capacité mentale." } }, { "@type": "Question", "name": "Comment le stress impacte-t-il la capacité mentale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut entraîner des troubles de la concentration et de la mémoire." } }, { "@type": "Question", "name": "Les troubles du sommeil influencent-ils la capacité mentale ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un sommeil insuffisant peut nuire à la mémoire et à la prise de décision." } }, { "@type": "Question", "name": "Quels changements de comportement signalent une altération ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Isolement social, irritabilité, et changements d'humeur fréquents peuvent être des signes." } }, { "@type": "Question", "name": "Comment prévenir l'altération de la capacité mentale ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir une vie active, équilibrée et socialement engagée aide à prévenir les troubles." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la capacité mentale ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en oméga-3 et antioxydants favorise la santé cognitive." } }, { "@type": "Question", "name": "Le contrôle du stress est-il important ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques de gestion du stress comme la méditation peuvent aider à préserver la cognition." } }, { "@type": "Question", "name": "Les activités mentales préventives sont-elles efficaces ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeux de réflexion et la lecture stimulent le cerveau et peuvent retarder le déclin." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il nécessaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des bilans réguliers permettent de détecter précocement des troubles cognitifs." } }, { "@type": "Question", "name": "Quels traitements existent pour améliorer la capacité mentale ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie cognitive, la médication et les exercices mentaux." } }, { "@type": "Question", "name": "La rééducation cognitive est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à restaurer certaines fonctions cognitives et à améliorer la prise de décision." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider à la capacité mentale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs de la cholinestérase sont souvent prescrits pour les troubles cognitifs." } }, { "@type": "Question", "name": "La thérapie de groupe est-elle bénéfique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle favorise le soutien social et peut améliorer la cognition par l'interaction." } }, { "@type": "Question", "name": "Les exercices physiques aident-ils la capacité mentale ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier améliore la circulation sanguine et la santé cognitive." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une capacité mentale altérée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'incapacité à gérer les finances et les soins personnels." } }, { "@type": "Question", "name": "L'isolement social est-il une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes avec une capacité mentale altérée peuvent s'isoler, aggravant leur état." } }, { "@type": "Question", "name": "Les accidents sont-ils plus fréquents chez ces patients ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une altération de la capacité mentale augmente le risque d'accidents domestiques." } }, { "@type": "Question", "name": "Comment la capacité mentale altérée affecte-t-elle les relations ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des conflits familiaux et des difficultés de communication." } }, { "@type": "Question", "name": "Les troubles mentaux peuvent-ils aggraver d'autres maladies ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une capacité mentale altérée peut aggraver des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour une altération de la capacité mentale ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, les antécédents familiaux et les maladies chroniques sont des facteurs de risque." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la capacité mentale ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un déclin cognitif accru et à des troubles mentaux." } }, { "@type": "Question", "name": "Le manque d'activité physique est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inactivité physique est liée à un risque accru de déclin cognitif." } }, { "@type": "Question", "name": "Les traumatismes crâniens augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traumatismes crâniens peuvent entraîner des troubles cognitifs à long terme." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils des facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles de l'humeur comme la dépression augmentent le risque de déclin cognitif." } } ] } ] }

Sources (10000 au total)

Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.

Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are frequently discontinued in patients with chronic kidney disease (CKD). Documented adverse drug reactions (... In this retrospective cohort of US veterans from 2005 to 2019, we identified individuals with CKD and a current prescription for an ACEi or ARB (current user group) or a discontinued prescription with... There were 882,441 (73.0%) individuals in the current user group and 326,794 (27.0%) in the discontinued group. There were 26,434 documented ADRs, with at least one documented ADR in 7,520 (0.9%) curr... ADRs leading to drug discontinuation were infrequently documented. ADR types were differentially associated with treatment discontinuation. An understanding of which ADRs lead to treatment discontinua...

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.

Diabetic kidney disease (DKD) is a common disorder with multiple serious clinical implications, including an increased risk of end-stage kidney disease (ESKD), cardiovascular complications, heart fail... Upregulation of the renin-angiotensin-aldosterone system is an important contributor to kidney disease progression, as highlighted by the results of trials evaluating angiotensin-converting enzyme inh... Aldosterone can promote kidney disease in diabetes via the MR and via MR-independent actions through Rac1. However, the MR remains a key element of this triangle, with clinical data supporting the use...

Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.

Background PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of sacu...

Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort.

Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are known to be effective in managing cardiovascular diseases, but more evidence supports the use of a... Patients who were first prescribed ACEIs or ARBs at two tertiary university hospitals in Korea were observed in this retrospective cohort study for the incidence of heart failure, angina, acute myocar... Overall, 2,945 and 9,189 patients were prescribed ACEIs and ARBs, respectively. When compared to ACEIs, the incidence of heart failure decreased by 52% in those taking ARBs (HR [95% CI] = 0.48 [0.39-0... ARBs were not inferior to ACEIs in relation to reducing the incidence of cardiocerebrovascular disease in the clinical setting; however, there were slight differences for each disease. The greatest st...

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction.

There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-c...

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Chronic kidney disease (CKD) is a long-term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated ... To evaluate the benefits and harms of ACEi and ARB or both in the management of people with early (stage 1 to 3) CKD who do not have diabetes mellitus (DM).... We searched the Cochrane Kidney and Transplant Register of Studies up to 6 July 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register... Randomised controlled trials (RCTs) reporting the effect of ACEi or ARB in people with early (stage 1 to 3) CKD who did not have DM were selected for inclusion. Only studies of at least four weeks dur... Data extraction was carried out by two authors independently, using a standard data extraction form. The methodological quality of included studies was assessed using the Cochrane risk of bias tool. D... There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM. The available evidence is overall of very low certainty and...

The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.

Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 bloc... We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated with immune checkpoint inhibitors (ICIs) across all types of cance... A total of 167 patients receiving both angiotensin receptor blockers (ARBs) and immune checkpoint inhibitors (ICIs) were included. Compared with non-PPAR-γ-ARB users (n = 102), PPAR-γ-ARB users (n = 6... The use of ARBs with PPAR-γ-activating property is linked with better survival among patients receiving ICIs....

Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Unstable Angina with Preserved Left Ventricular Systolic Function.

The present study evaluated the clinical results of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment in patients with unstable angina (UA) with preserved ...